Strasbourg biotech appoints ceo
Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection
Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.
Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.
Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.
‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.
You may also like
Pharmaceutical
Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024
Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Pharmaceutical
At Pack Expo 2024, Antares Vision Group to debut versatile, high-speed serialization station for pharma bottles of various shapes and sizes
Antares Vision Group will also introduce a serialization module for flat cartons and demonstrate a high-speed automated visual inspection unit for liquid-filled vials